Corporate
News Releases
2024
September
Pharmaceuticals
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight® hematological malignancies gene panel test approved in Japan -
Corporate
Heartful Kawauchi ReceivedJapan Organization for Employment of the Elderly, Persons with Disabilities and Job Seekers President's Award
Nutraceuticals
Otsuka Pharmaceutical Advancing Women's Health Business Bonafide Health Launched "Thermella", a Plant-derived Supplement to Support Menopausal Women in the U.S.
Pharmaceuticals
Otsuka Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease
Pharmaceuticals
Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis
Pharmaceuticals
Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuticals
Otsuka to Participate in the Orange Innovation Project, Promoted by Japan's Ministry of Economy, Trade and Industry
Corporate
Otsuka Pharmaceutical Launches Corporate Health Support Program "fitbiz"Supporting Employees in Building and Maintaining Healthy Habits
Nutraceuticals
Otsuka Pharmaceutical signs global supporter agreement with World AthleticsSponsorship will cover the World Athletics Championships Tokyo 25POCARI SWEAT will support the event with the key message "Believe In Your Potential."
Pharmaceuticals
Otsuka and Jolly Good Launch FACEDUO Dementia Care Support VR
Nutraceuticals
New from the Skincare Brand sakuraé Introducing Sakuraé Clear Cycle Lotion for Translucent and Healthy Skin
Nutraceuticals
U.S. Originated Nutrition Tracking Service "Vivoo" Launches in Japan Providing Easy Access to Nutritional Data to Support Healthy Lifestyles
August
Pharmaceuticals
Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn™, the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms ーRejoyn, a first-of-its-kind digital treatment designed to help with cognitive control of emotion, is now available in mobile app stores and can be unlocked with a prescription from a healthcare providerー
Corporate
Otsuka Pharmaceutical Joins Project to Promote Use of Sustainable Aviation Fuel in Air Cargo TransportationーOperated by Tokyo Metropolitan Government, Aiming for a Decarbonized Societyー
Pharmaceuticals
Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024
Corporate
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. - Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) - - Expands Specialty and Autoimmune Portfolios and Drug Discovery Technologies -
July
June
Pharmaceuticals
Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)
Nutraceuticals
Introducing a New Calorie Mate Block Production LineDeveloping a Sustainable Factory that is Kind to the Environment and Employees
Pharmaceuticals
Otsuka Concludes Expanded Licensing Agreement for Donidalorsen in Hereditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan
Nutraceuticals
Korea Otsuka Pharmaceutical Launches Soy Bar "SOYJOY"Introducing a New Concept of Healthy Snacking
May
Corporate
Otsuka Pharmaceutical and Taiho PharmaceuticalCommence Material Recycling of Waste PTP Used in Pharmaceutical Packaging
Nutraceuticals
InnerSignal Introduces a New Basic Skincare Line Launch of "Repair Lotion" and "Repair Milk" to Address Epidermal Imbalance
Pharmaceuticals
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Pharmaceuticals
Otsuka to Terminate Development of AVP-786
Pharmaceuticals
Novartis launches Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients
Pharmaceuticals
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment of Hypercholesterolemia
Nutraceuticals
Carbonated Nutritional Drink "ORONAMIN C DRINK" Debuts in Egypt
April
Pharmaceuticals
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Pharmaceuticals
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry in the U.S.
Pharmaceuticals
FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -
Pharmaceuticals
U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital Therapeutic Authorized in the U.S. for the Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms
March
Pharmaceuticals
Submission of an Application for the First Hematological Malignancies Gene Panel Test in Japan
Pharmaceuticals
Abilify Maintena® 960mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
Pharmaceuticals
Novartis receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients with chronic heart failure
Pharmaceuticals
Otsuka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
Pharmaceuticals
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Pharmaceuticals
Otsuka and Lundbeck Presented New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease
Corporate
Otsuka Pharmaceutical Enters into Cooperation Agreement on Heat Illness Prevention with Environmental Restoration and Conservation Agency
Pharmaceuticals
Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 70.1 KB)
Nutraceuticals
New SOYJOY Fig & Raisin A Whole-Soy Nutrition Bar Enhanced with Flavorful Figs
February
Pharmaceuticals
Otsuka Enters into Investment Contract with AN Venture Partners
Nutraceuticals
Otsuka Sponsors TOKYO MARATHON 2024 POCARI SWEAT Supports Runners Achieve Their Goals
Nutraceuticals
Launch of AR-Based Nutrition Education Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town
Pharmaceuticals
Sibeprenlimab Received U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy (IgAN)
Corporate
Otsuka Pharmaceutical Launches "Kenkokeiei Tsunagaru Support ONLINE"Broadening Support for Resolving Corporate Health Challenges
Pharmaceuticals
Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
Pharmaceuticals
Novartis Obtains Approval for Additional Indication of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto® Tablet = Novartis and Otsuka to provide information to healthcare professionals on additional indication for Entresto =
Pharmaceuticals
Otsuka and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support
Corporate